COLTS NECK, N.J.--(www.unitedhealthproductsinc.com (OTCQB: UEEC.PK) wholly owned subsidiary, Epic Wound Care, Inc., which develops and markets products and technologies in the healthcare sector, is pleased to announce that it has entered into a beta test agreement with the distinguished Ryan Network for UEEC's hemostatic gauze. The gauze is registered and branded in the USA under the trademark HemoStyp™. Under the beta test protocol, the HemoStyp™ gauze will be indicated for patients post venipuncture to assess expedited coagulation, ease of use, patient satisfaction, and decrease prolonged coagulation due to patients co-morbidities and anticoagulation therapy. The Ryan Network was founded upon former Congressman William F. Ryan's belief that "health care is a right, not a privilege." Ryan Network is a family of not-for-profit, federally qualified health centers with multiple locations in New York City. In July 2011, medical residents and attending preceptor physicians from St. Luke's-Roosevelt Hospital Center (SLRHC) began providing front-line primary medical care in Ryan's Adult Medicine Department as part of their training in the Medical Residency Program/SLRHC. The Network's other sites, Ryan-NENA (2011 - Beth Israel Hospital), Ryan Chelsea-Clinton (2007 - Roosevelt Hospital) and Ryan/Adair (2009 - SLRHC), also have medical residents in place (in some cases, for several years), to the mutual benefit of Ryan's patients and the Medical Residency Program. The Network's service sites also include the new Ryan Women & Children's Center, clinics at four family living transitional shelters, one rehabilitation center and six school-based health centers. The service sites are fully coordinated with all services at the main center sites.)--United Health Products, Inc.'s
“The Ryan Network delivers world-class medical care to diverse and underserved communities, and their commitment to the beta testing is one more way they can deliver on that promise to those communities.”
HemoStyp™ is a gauze specifically formulated to produce hemostasis almost instantly when positioned on a cut or wound. It contains no potentially harmful chemicals such as thrombin, collagen or animal byproducts, is hypoallergenic and works more quickly than other hemostatic agents. Once it has completed its task, it is readily dissolved by saline solution or water for easy removal that neither disturbs the clotted surface nor encourages re-bleeding.
Dr. Phillip Forman, CEO of United Health Products Inc., stated, "The Ryan Network delivers world-class medical care to diverse and underserved communities, and their commitment to the beta testing is one more way they can deliver on that promise to those communities.” Dr. Forman hoped to have the results of the specific study parameters and data collection available within 60 days.
More information about the Ryan Network can be found here: http://www.ryancenter.org/home.htm
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets products and technologies in the healthcare sector. UEEC's operating subsidiary Epic Wound Care, Inc. produces hemostatic gauze, derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying emerging healthcare products and technologies for strategic partnership or acquisition. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.